NuDroxiPAK | Medidex

×

Overview

What is NuDroxiPAK?

Celecoxib capsules are a nonsteroidal anti-inflammatory drug, available as capsules containing 50 mg, 100 mg, and 200 mg celecoxib for oral administration. The chemical name is 4-[5-(4-methylphenyl)- 3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide and is a diaryl-substituted pyrazole. The empirical formula is C17H14F3N3O2S, and the molecular weight is 381.38; the chemical structure is as follows:

Celecoxib capsules for oral administration contain either 50 mg, 100 mg, or 200 mg of celecoxib, together with inactive ingredients including: crospovidone, sodium lauryl sulphate, povidone, magnesium stearate. The capsule shell contains gelatin and titanium dioxide. The capsule imprinting ink for the 50 mg strength contains shellac, ethyl alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, sodium hydroxide, titanium dioxide, povidone and FD&C Red #40 Aluminum Lake. The capsule imprinting ink for the 100 mg strength contains shellac, ethyl alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, and FD&C Blue #2 Aluminum Lake. The capsule imprinting ink for the 200 mg strength contains shellac, ethyl alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, yellow iron oxide, and dimethicone.

What does NuDroxiPAK look like?

What are the available doses of NuDroxiPAK?

Capsules: 50 mg, 100 mg and 200 mg ( )

What should I talk to my health care provider before I take NuDroxiPAK?

How should I use NuDroxiPAK?

Use for the temporary relief of minor aches and muscle pains associated with arthritis, simple backache, strains, muscle soreness and stiffness.

What interacts with NuDroxiPAK?

Sorry No Records found

What are the warnings of NuDroxiPAK?

Sorry No Records found

What are the precautions of NuDroxiPAK?

Sorry No Records found

What are the side effects of NuDroxiPAK?

Sorry No records found

What should I look out for while using NuDroxiPAK?

Celecoxib capsules are contraindicated in the following patients

:

For external use only. Use only as directed. Avoid contact with eyes and mucous membranes or genitals. Do not cover or tightly bandage area. on wounds or damaged skin. Do not use with heating pad.

What might happen if I take too much NuDroxiPAK?

Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare [ ].

No overdoses of celecoxib were reported during clinical trials. Doses up to 2400 mg/day for up to 10 days in 12 patients did not result in serious toxicity. No information is available regarding the removal of celecoxib by hemodialysis, but based on its high degree of plasma protein binding (>97%) dialysis is unlikely to be useful in overdose.

Manage patients with symptomatic and supportive care following an NSAID overdosage. There are no specific antidotes. Consider emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients seen within four hours of ingestion or in patients with a large overdosage (5 to 10 times the recommended dosage). Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.

For additional information about overdosage treatment contact a poison control center (1-800-222-1222).

How should I store and handle NuDroxiPAK?

Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8 Celecoxib capsules 50 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C50” is imprinted on each capsule in red ink. They are supplied as follows:Bottles of 30s NDC 60505-3847-3Bottles of 60s NDC 60505-3847-6Bottles of 100s NDC 60505-3847-1 Bottles of 1,000 NDC 60505-3847-8 Celecoxib capsules 100 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C100” is imprinted on each capsule in blue ink. They are supplied as follows:Bottles of 30s NDC 60505-3848-3Bottles of 100s NDC 60505-3848-1 Bottles of 500s NDC 60505-3848-5 Bottles of 1,000 NDC 60505-3848-8 Celecoxib capsules 200 mg are available for oral administration as hard gelatin capsules with a white opaque body and a white opaque cap. “APO C200” is imprinted on each capsule in yellow ink. They are supplied as follows:Bottles of 30s NDC 60505-3849-3Bottles of 100s NDC 60505-3849-1 Bottles of 500s NDC 60505-3849-5 Bottles of 1,000 NDC 60505-3849-8

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Celecoxib has analgesic, anti-inflammatory, and antipyretic properties.

The mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of cyclooxygenase-2 (COX-2).

Celecoxib is a potent inhibitor of prostaglandin synthesis . Celecoxib concentrations reached during therapy have produced effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Since celecoxib is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.

Non-Clinical Toxicology

Celecoxib capsules are contraindicated in the following patients

:

For external use only. Use only as directed. Avoid contact with eyes and mucous membranes or genitals. Do not cover or tightly bandage area. on wounds or damaged skin. Do not use with heating pad.

Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses. Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.

In the APC (Adenoma Prevention with Celecoxib) trial, the hazard ratio for the composite endpoint of cardiovascular death, MI, or stroke was 3.4 (95% CI 1.4 – 8.5) for celecoxib capsules 400 mg twice daily and 2.8 (95% CI 1.1 – 7.2) with celecoxib capsules 200 mg twice daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects), respectively, compared to 0.9% (6/679 subjects) with placebo treatment. The increases in both celecoxib dose groups versus placebo-treated patients were mainly due to an increased incidence of myocardial infarction [ ]. In the APC (Adenoma Prevention with Celecoxib) trial, the hazard ratio for the composite endpoint of cardiovascular death, MI, or stroke was 3.4 (95% CI 1.4 – 8.5) for celecoxib capsules 400 mg twice daily and 2.8 (95% CI 1.1 – 7.2) with celecoxib capsules 200 mg twice daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects), respectively, compared to 0.9% (6/679 subjects) with placebo treatment. The increases in both celecoxib dose groups versus placebo-treated patients were mainly due to an increased incidence of myocardial infarction [ ].

minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as celecoxib, increases the risk of serious gastrointestinal (GI) events [ ]. To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as celecoxib, increases the risk of serious gastrointestinal (GI) events [ ].

Two large, controlled clinical of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG [ ]. Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG [ ].

Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all- mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up. Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all- cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.

Avoid the use of celecoxib in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If celecoxib is used in patients with a recent MI, monitor for signs of cardiac ischemia. Avoid the use of celecoxib in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If celecoxib is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

The following adverse reactions are discussed in greater detail in other sections of the labeling:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Disclaimer:

Celecoxib,Methyl Salicylate/Menthol/Capsaicin

Overview

What is NuDroxiPAK?

What does NuDroxiPAK look like?

What are the available doses of NuDroxiPAK?

What should I talk to my health care provider before I take NuDroxiPAK?

How should I use NuDroxiPAK?

What interacts with NuDroxiPAK?

What are the warnings of NuDroxiPAK?

What are the precautions of NuDroxiPAK?

What are the side effects of NuDroxiPAK?

What should I look out for while using NuDroxiPAK?

What might happen if I take too much NuDroxiPAK?

How should I store and handle NuDroxiPAK?

Clinical Information

Chemical Structure

Clinical Pharmacology

Non-Clinical Toxicology

Reference

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

Review

Rate this treatment and share your opinion

Helpful tips to write a good review:

Reason for Taking This Treatment

Click the stars to rate this treatment

Effectiveness (required)

Ease of Use (required)

Satisfaction (required)

Write a brief description of your experience with this treatment:

Optional Information

User Reviews & Ratings - losartan oral

«losartan oral Information

Overall User Ratings

User Reviews
Learn about User Reviews

Related to losartan oral

Professional

Tips

Interactions

Follow Us Here

Disclaimer:

Celecoxib,Methyl Salicylate/Menthol/Capsaicin

Overview

What is NuDroxiPAK?

What does NuDroxiPAK look like?

What are the available doses of NuDroxiPAK?

What should I talk to my health care provider before I take NuDroxiPAK?

How should I use NuDroxiPAK?

What interacts with NuDroxiPAK?

What are the warnings of NuDroxiPAK?

What are the precautions of NuDroxiPAK?

What are the side effects of NuDroxiPAK?

What should I look out for while using NuDroxiPAK?

What might happen if I take too much NuDroxiPAK?

How should I store and handle NuDroxiPAK?

Clinical Information

Chemical Structure

Clinical Pharmacology

Non-Clinical Toxicology

Reference

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

Review

Rate this treatment and share your opinion

Helpful tips to write a good review:

Reason for Taking This Treatment

Click the stars to rate this treatment

Effectiveness (required)

Ease of Use (required)

Satisfaction (required)

Write a brief description of your experience with this treatment:

Optional Information

User Reviews & Ratings - losartan oral

«losartan oral Information

Overall User Ratings

User Reviews Learn about User Reviews

Related to losartan oral

Professional

Tips

Interactions

Follow Us Here

User Reviews
Learn about User Reviews